Immunomodulatory Effects of Pevonedistat, a NEDD8-Activating Enzyme (NAE) Inhibitor, in Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Best, Scott R. [1 ]
Kittai, Adam [2 ]
Rowland, Taylor [1 ]
Bruss, Nur [1 ]
Spurgeon, Stephen E. [2 ]
Berger, Allison [3 ]
Moran, Amy [1 ]
Danilov, Alexey V. [2 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[3] Takeda Pharmaceut Int Co, Oncol Drug Discovery Unit, Cambridge, MA USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-115086
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2946
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924
    Milhollen, Michael A.
    Thomas, Michael P.
    Narayanan, Usha
    Traore, Tary
    Riceberg, Jessica
    Amidon, Benjamin S.
    Bence, Neil F.
    Bolen, Joseph B.
    Brownell, James
    Dick, Lawrence R.
    Loke, Huay-Keng
    McDonald, Alice A.
    Ma, Jingya
    Manfredi, Mark G.
    Sells, Todd B.
    Sintchak, Mike D.
    Yang, Xiaofeng
    Xu, Qing
    Koenig, Erik M.
    Gavin, James M.
    Smith, Peter G.
    CANCER CELL, 2012, 21 (03) : 388 - 401
  • [22] Pediatric Preclinical Testing Program (PPTP) evaluation of the NEDD8-activating enzyme (NAE) inhibitor MLN4924
    Carol, Hernan
    Lock, Richard B.
    Maris, John M.
    Keir, Stephen T.
    Gorlick, Richard
    Kolb, E. Anders
    Kang, Min H.
    Reynolds, C. Patrick
    Morton, Christopher L.
    Smith, Peter G.
    Thomas, Michael
    McDonald, Alice
    Houghton, Peter J.
    Smith, Malcolm A.
    CANCER RESEARCH, 2011, 71
  • [23] An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
    Soucy, Teresa A.
    Smith, Peter G.
    Milhollen, Michael A.
    Berger, Allison J.
    Gavin, James M.
    Adhikari, Sharmila
    Brownell, James E.
    Burke, Kristine E.
    Cardin, David P.
    Critchley, Stephen
    Cullis, Courtney A.
    Doucette, Amanda
    Garnsey, James J.
    Gaulin, Jeffrey L.
    Gershman, Rachel E.
    Lublinsky, Anna R.
    McDonald, Alice
    Mizutani, Hirotake
    Narayanan, Usha
    Olhava, Edward J.
    Peluso, Stephane
    Rezaei, Mansoureh
    Sintchak, Michael D.
    Talreja, Tina
    Thomas, Michael P.
    Traore, Tary
    Vyskocil, Stepan
    Weatherhead, Gabriel S.
    Yu, Jie
    Zhang, Julie
    Dick, Lawrence R.
    Claiborne, Christopher F.
    Rolfe, Mark
    Bolen, Joseph B.
    Langston, Steven P.
    NATURE, 2009, 458 (7239) : 732 - U67
  • [24] An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
    Teresa A. Soucy
    Peter G. Smith
    Michael A. Milhollen
    Allison J. Berger
    James M. Gavin
    Sharmila Adhikari
    James E. Brownell
    Kristine E. Burke
    David P. Cardin
    Stephen Critchley
    Courtney A. Cullis
    Amanda Doucette
    James J. Garnsey
    Jeffrey L. Gaulin
    Rachel E. Gershman
    Anna R. Lublinsky
    Alice McDonald
    Hirotake Mizutani
    Usha Narayanan
    Edward J. Olhava
    Stephane Peluso
    Mansoureh Rezaei
    Michael D. Sintchak
    Tina Talreja
    Michael P. Thomas
    Tary Traore
    Stepan Vyskocil
    Gabriel S. Weatherhead
    Jie Yu
    Julie Zhang
    Lawrence R. Dick
    Christopher F. Claiborne
    Mark Rolfe
    Joseph B. Bolen
    Steven P. Langston
    Nature, 2009, 458 : 732 - 736
  • [25] A natural product-like inhibitor of NEDD8-activating enzyme
    Leung, Chung-Hang
    Chan, Daniel Shiu-Hin
    Yang, Hui
    Abagyan, Ruben
    Lee, Simon Ming-Yuen
    Zhu, Guo-Yuan
    Fong, Wang-Fun
    Ma, Dik-Lung
    CHEMICAL COMMUNICATIONS, 2011, 47 (09) : 2511 - 2513
  • [26] Clinical pharmacodynamic assay development for the first small molecule inhibitor of Nedd8-activating enzyme (NAE), MLN4924
    Garnsey, James Joseph
    Walker, Russell M.
    Pickard, Michael D.
    Traore, Tary
    Thomas, Michael
    Zhang, Julie
    Xia, Cindy
    Zhang, Ji
    Mulligan, George
    Smith, Peter G.
    Berger, Allison J.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [27] Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis
    Paiva, Cody
    Godbersen, J. Claire
    Rowland, Taylor
    Danilova, Olga V.
    Danes, Christopher
    Berger, Allison
    Danilov, Alexey V.
    ONCOTARGET, 2017, 8 (13) : 21128 - 21139
  • [28] SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy
    Zhou, Li-Na
    Xiong, Chaodong
    Cheng, Yong-Jun
    Song, Shan-Shan
    Bao, Xu-Bin
    Huan, Xia-Juan
    Wang, Tong-Yan
    Zhang, Ao
    Miao, Ze-Hong
    He, Jin-Xue
    NEOPLASIA, 2022, 32
  • [29] Antitumor activity of MLN4924, an investigational inhibitor of NEDD8-activating enzyme (NAE), in preclinical models of melanoma.
    Traore, T.
    Mihollen, M.
    Garnsey, J.
    Berger, A.
    Manfredi, M.
    Cosmopolous, K.
    Donelan, J.
    Smith, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non- Hodgkin Lymphoma (NHL)
    Torka, Pallawi
    Kambhampati, Swetha
    Muir, Alexandra
    Orand, Kirsten
    Smith, Lynne
    Herrera, Alex F.
    Lewis, Lionel
    Hernandez-Ilizaliturri, Francisco J.
    Chen, Lu
    Danilov, Alexey V.
    BLOOD, 2021, 138
12345